GlassScriptPhysician profile
Susan Hostetter
NPI 1205971108
$2,276.19
in general payments reported to CMS, 2019-2025
21 companies · $199 in 2025
The $199 reported for 2025 was more than what 75% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $679 · 2023: $715 · 2024: $227 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $484.67 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $463.07 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $226.83 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $163.90 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $148.95 | 2022-2024 | Jornay Pm |
| Corium, LLC | $139.85 | 2022-2023 | Azstarys |
| Alkermes, INC. | $103.70 | 2021-2023 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $93.28 | 2022-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $77.63 | 2021-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.66 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $54.43 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $48.33 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $46.73 | 2025 | Jornay Pm |
| Pfizer INC. | $26.16 | 2024 | |
| Sanofi Pasteur INC. | $25.10 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $23.40 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $23.27 | 2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $21.47 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $18.96 | 2022 | |
| Lnhc, INC | $16.58 | 2025 | Zelsuvmi |
| Cranial Technologies, INC | $15.22 | 2025 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Hostetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.